Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3781344 | 0.75 | ALDH1A1 (0.39) | ALDH1A1GAA | |
| SCHEMBL532620 | 0.72 | ENPP2 (0.34) | — | |
| SCHEMBL17398210 | 0.70 | CYP2A6 (0.39) | ALDH1A1 | |
| SCHEMBL29954338 | 0.70 | PGR (0.33) | — | |
| SCHEMBL28875003 | 0.70 | — | — | |
| SCHEMBL3783537 | 0.67 | HPGD (0.31) | — | |
| SCHEMBL7194664 | 0.65 | ALDH1A1 (0.50) | ALDH1A1TSHRALOX5GAAHTT | |
| SCHEMBL3782240 | 0.64 | ALDH1A1 (0.34) | ALDH1A1GAA | |
| SCHEMBL13889735 | 0.63 | ALDH1A1 (0.36) | ALDH1A1TSHRALOX5GAAHTT | |
| SCHEMBL8538414 | 0.62 | ALDH1A1 (0.32) | ALDH1A1ALOX5GAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12083121-B2 | Substituted piperazines as KRAS G12C inhibitors | AMGEN INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240279627-A1 | COMPOSITIONS COMPRISING A LIPOLYTIC ENZYME VARIANT AND METHODS OF USE THEREOF | DANISCO US INC (US) | 2024-08-22 | — | — | US | disclosed |
| CN-118063461-A | Red light/near infrared photochromic molecule, preparation method and application thereof | 华东理工大学 | 2024-05-24 | — | — | CN | disclosed |
| US-20230049452-A1 | COMPOSITIONS COMPRISING A LIPOLYTIC ENZYME VARIANT AND METHODS OF USE THEREOF | DANISCO US INC (US) | 2023-02-16 | — | — | US | disclosed |
| EP-4090727-A1 | COMPOSITIONS COMPRISING A LIPOLYTIC ENZYME VARIANT AND METHODS OF USE THEREOF | Danisco US Inc. (US) | 2022-11-23 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220324814-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS INC (US) | 2022-10-13 | — | — | US | disclosed |
| CN-110191882-B | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | 株式会社大熊制药 | 2022-09-13 | — | — | CN | disclosed |
| US-20220175782-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-06-09 | — | — | US | disclosed |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| WO-2010036497-A2 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | ELI LILLY AND COMPANY (US) | 2010-04-01 | — | — | WO | disclosed |
| EP-1648864-A4 | PHOTOCHROMIC DIARYLETHENE-CONTAINING COORDINATION COMPOUNDS AND THE PRODUCTION THEREOF | UNIV HONG KONG (CN) | 2009-08-19 | — | — | EP | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-7355775-B2 | Photochromic diarylethene-containing coordination compounds and the production thereof | THE UNIVERSITY OF HONG KONG (CN) | 2008-04-08 | — | — | US | disclosed |
| US-7355775-B2 | Photochromic diarylethene-containing coordination compounds and the production thereof | THE UNIVERSITY OF HONG KONG (CN) | 2008-04-08 | — | — | US | disclosed |
| US-20070057240-A1 | extends excitation wavelength for the photocyclization of the diarylethene moiety from lambda <== 340 nm to lower energy, so that the photochromic forward reaction can proceed with visible light excitation by utilization of the low-energy absorptions characteristic | UNIVERSITY OF HONG KONG, THE (CN) | 2007-03-15 | — | — | US | disclosed |
| US-20070057240-A1 | extends excitation wavelength for the photocyclization of the diarylethene moiety from lambda <== 340 nm to lower energy, so that the photochromic forward reaction can proceed with visible light excitation by utilization of the low-energy absorptions characteristic | UNIVERSITY OF HONG KONG, THE (CN) | 2007-03-15 | — | — | US | disclosed |
| EP-1648864-A1 | PHOTOCHROMIC DIARYLETHENE-CONTAINING COORDINATION COMPOUNDS AND THE PRODUCTION THEREOF | The University of Hong Kong (CN) | 2006-04-26 | — | — | EP | disclosed |
| US-20050033072-A1 | Photochromic diarylethene-containing coordination compounds and the production thereof | UNIVERSITY OF HONG KONG, THE (CN) | 2005-02-10 | — | — | US | disclosed |
| WO-2005003126-A1 | PHOTOCHROMIC DIARYLETHENE-CONTAINING COORDINATION COMPOUNDS AND THE PRODUCTION THEREOF | THE UNIVERSITY OF HONG KONG (CN) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070057240-A1 | extends excitation wavelength for the photocyclization of the diarylethene moiety from lambda <== 340 nm to lower energy, so that the photochromic forward reaction can proceed with visible light excitation by utilization of the low-energy absorptions characteristic | CYBA, POLL, CRY1 | ALDH1A1 875/4885TSHR 4810/4885ALOX5 3748/4885 |
| US-20050033072-A1 | Photochromic diarylethene-containing coordination compounds and the production thereof | CRY1, CRY2, DDT | ALDH1A1 1804/4885TSHR 4722/4885ALOX5 4386/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | ALDH1A1 4193/4885TSHR 4380/4885ALOX5 3759/4885 |
| US-20220324814-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | ALDH1A1 4193/4885TSHR 4380/4885ALOX5 3759/4885 |
| US-12083121-B2 | Substituted piperazines as KRAS G12C inhibitors | KRAS, NRAS, HRAS | ALDH1A1 3126/4885TSHR 4241/4885ALOX5 3984/4885 |
| US-20220175782-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | ALDH1A1 4307/4885TSHR 4516/4885ALOX5 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.